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OBJECTIVES The purpose of this study was to assess safety and effectiveness of the fourth generation
buttoned device in closing atrial septal defects (ASDs) and to test the hypothesis that
introduction of double button reduces unbuttoning rate without reducing effectiveness.
BACKGROUND Because of the high unbuttoning rate (7.2%) with first, second and third generation buttoned
devices, the device was modified (fourth generation) so that there were two radiopaque spring
buttons 4 mm apart on the button loop attached to the occluder.
METHODS During a four-year period ending in September 1997, 423 patients, ages 1.5 to 80 years
(median 16 years), underwent closure of ASD at 40 medical centers around the world.
RESULTS The ASD size varied between 5 and 30 mm (median 17 mm). The device size varied between
25 and 60 mm. Unbuttoning occurred in 4 (0.9%) of 423 patients. Effective occlusion, defined
as no (n 5 343) or trivial (n 5 34) residual shunt on echo-Doppler studies performed within
24 h of the procedure, was demonstrated in 377 patients (90%). Thus, the unbuttoning rate
(0.9 vs. 7.2%) decreased (p , 0.01) while effective occlusion rate (90 vs. 92%) remained
unchanged (p . 0.1) with this device, compared with earlier generation devices. During
follow-up from one month to five years (23 6 15 months), 21 (5%) of 417 patients required
surgical (n 5 12) or transcatheter (n 5 9) reintervention, mostly to treat significant residual
shunt. In the remaining patients there was gradual reduction and disappearance of the
residual shunt. No wire integrity problems were observed.
CONCLUSIONS These data suggest that the fourth generation buttoned device is as effective as earlier
generation devices, but without significant unbuttoning. Follow-up results remained good,
with a reintervention-free rate of 89% at five years. (J Am Coll Cardiol 2000;36:583–92) ©
2000 by the American College of Cardiology
Feasibility, safety and effectiveness of transvenous closure of
ostium secundum atrial septal defects (ASDs) with first,
second and third generation buttoned devices (BDs) have
been shown in our previous studies (1–4). However, in the
international study (4), detachment of the occluder and
counter-occluder components of the device from each other,
termed unbuttoning, was observed in 7.2% of the implan-
tations, requiring transcatheter or surgical retrieval of the
device. Because of this phenomenon, the device was mod-
ified to have two spring buttons (Fig. 1) instead of the single
button in the earlier devices. This presentation reviews our
experience with the fourth generation BD, assesses imme-
diate and follow-up results with the modified device and
compares the results with those of earlier BDs, particularly
to validate the hypothesis that the double button modifica-
tion of the device decreases unbuttoning rate while main-
taining the immediate and follow-up effectiveness of early
generation devices.
SUBJECTS AND METHODS
During a four-year period ending in September 1997, 475
patients were taken to catheterization laboratories with the
intent to occlude the ASD with the fourth generation BD.
Protocol. The transcatheter ASD occlusion was under-
taken under a protocol approved by the Institutional Review
Board at each participating hospital as per local regulations,
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and subject to FDA approval for clinical trials with inves-
tigational device exemption in the cases performed in the
U.S. hospitals. Informed consent was obtained from the
parents or the patients as appropriate.
Inclusion/exclusion criteria. Patients with ostium secun-
dum ASDs with echocardiographic (ECHO) evidence for
right ventricular volume overloading and/or a pulmonary to
systemic flow ratio (Qp:Qs) .1.5 during cardiac catheter-
ization are included in the study. Patients with stretched
ASD diameter (4–6) .30 mm did not undergo device
closure of their ASDs. Patients with patent foramen ovale
(PFO)/ASD who had cerebrovascular events presumably
secondary to paradoxical embolism (7) were not included in
this analysis. Patients with PFO/ASDs with right-to-left
shunt who underwent inverted BD closure (8) were also
excluded.
Device. The device is composed of three components: an
occluder, a counter-occluder and a delivery system, and has
been described in detail (1–4,9). In the fourth generation
device used in the current study, the button loop attached to
the occluder was modified so that there were two ra-
diopaque spring buttons mounted 4 mm apart, in contrast to
one button in the first, second and third generation BDs
(Fig. 1).
The devices are manufactured in sizes from 25 through
60 mm, in 5-mm increments. Devices up to 55 mm are
available for use in the U.S.; all devices, including 60-mm
devices, are available outside the U.S.
Procedure. Following clinical and ECHO diagnosis and
informed consent, cardiac catheterization and selective left
atrial angiography were performed percutaneously via the
right femoral vein. A femoral arterial line was inserted to
monitor arterial pressures during the procedure and heparin
(100 U/kg, maximum 5,000 U) was administered. The
stretched diameter of the ASD was measured as previously
described (5,6). A long blue Cook sheath (Cook, Bloom-
ington, Indiana) was inserted into the left atrium; the size of
sheath varied, 8F, 9F or 11F, depending upon the size of the
device used and whether direct delivery or over-the-wire
technique was used for device implantation. The method of
device implantation by direct delivery has been described
(1–4). Device placement in the over-the-wire technique is
similar to direct delivery except that the soft end of a
0.025-in. Amplatz wire (Cook) is placed in a left pulmonary
vein and the central foam part (close to the middle of the X)
is pierced by the other end of the Amplatz wire; the wire is
Abbreviations and Acronyms
ASD 5 atrial septal defect
ASDOS5 atrial septal defect occluding system
BD 5 buttoned device
ECHO 5 echocardiogram
FDA 5 Food and Drug Administration
PFO 5 patent foramen ovale
Qp:Qs 5 pulmonary to systemic flow ratio
Figure 1. Cartoon depicting the occluder component of the second, third and fourth generation buttoned device. The occluder (Occ) in all devices is
composed of an x-shaped wire skeleton covered with 1/16-inch polyurethane foam. In the second generation device (left) a 2 mm string loop is attached
to the center of the occluder. The loop is closed with a knot (button) made radiopaque. This radiopaque button (ROB) can easily be visualized by
fluoroscopy. In the first generation device (not shown), the button was not radiopaque. A folded 0.008-inch nylon thread (NT) passes through the hollow
loading wire (LW) after passing through the loop in the center of the occluder. In the third generation device (middle) an extra loop is added immediately
beneath the radiopaque button. This modification converted the eccentric button of the second generation device to be aligned straight, thus making it easier
to button the Occ and counter-occluder across the atrial septum. In the fourth generation device (right), the button loop is replaced with two “spring”
radiopaque buttons (RB), mounted 4 mm apart. The intent was to reduce unbuttoning seen with earlier generation devices.
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removed at the conclusion of the procedure. Transesopha-
geal ECHO and fluoroscopic images of the device obtained
during the procedure are shown in Figures 2 and 3.
Following the procedure, three doses of cefazolin (25
mg/kg/dose in children and 1 g/dose in adults) were
administered intravenously. Aspirin (5 to 10 mg/kg/day in
children and 325 mg/day in adults) was orally administered
for a six-week period.
Follow-up. Clinical, chest roentgenographic and ECHO-
Doppler evaluation was performed 1 day and one, six and 12
months after the procedure and yearly thereafter. Clinical
examination was focused on detecting significant residual
shunt and the necessity for reintervention. Chest X-rays
were scrutinized for device position and to detect wire
fractures. ECHO-Doppler studies were reviewed to visual-
ize the position of the device and to detect residual shunts
which, if present, were quantitated as described previously
(4).
Definitions. The term occluder describes the left atrial
component of the BD consisting of an x-shaped wire
skeleton covered with 1/16-inch polyurethane foam.
Counter-occluder is a single-strand, Teflon-coated wire
skeleton covered with rhomboid-shaped polyurethane foam
with a rubber piece sutured in its center, and goes onto the
right atrial side of the defect. Unbuttoning is deemed to have
occurred if both the occluder and counter-occluder compo-
nents have separated from each other after having been
buttoned across the atrial septum. Effective occlusion is
defined as no or trivial residual shunt (4) across the ASD.
Complete occlusion implies no residual shunt.
Statistical methods. The data are expressed as mean 6 SD
for normally distributed variables. Median and ranges are
given for data that are not normally distributed. Paired t
tests were used to compare values before and after defect
Figure 2. Selected video frames from transesophageal echocardiographic
studies performed during an over-the-wire implantation of a fourth
generation buttoned device. a) Atrial septal defect (ASD) is shown (arrow).
b) and c) The occluder (Occ) component of the device at various positions
in the left atrium (LA) and the Amplatz wire (AW) passing through the
ASD and Occ is seen. d) The Occ on the left atrial side with a tiny residual
shunt (TRS) is shown (arrow).
Figure 3. Selected frames from a cineradiogram obtained during an over-the-wire implantation of a fourth generation buttoned device across the atrial
septum. a) and b) Postero-anterior views showing an Amplatz guide wire (AW) positioned into a left pulmonary vein. The occluder is delivered into the
left atrium (a) with tip of the sheath (Sh) in the right atrium. Radiopaque buttons (B) and loading wire (LW) are seen within the sheath. b) The
counter-occluder (COc) is delivered into the right atrium and buttoned. Note that the radiopaque wire of the COc is past the radiopaque buttons.
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occlusion, and independent sample t tests were performed
for between-group comparisons. When data were not nor-
mally distributed, appropriate nonparametric tests were
used. Categorical data were compared using chi-square
tests. Multivariate logistic regression analysis was performed
to identify predictors of residual shunt. Actuarial event-free
rates were derived by Kaplan-Meier method. Comparison
of event-free rates was performed by Mantel-Haenszel
(log-rank) test. The level of statistical significance was set at
p , 0.05 and was adjusted by Bonferroni correction when
multiple comparisons were made.
RESULTS
Four hundred and seventy-five patients at 40 institutions
around the world (see Appendix) were taken to catheteriza-
tion laboratories during a four-year period ending in Sep-
tember 1997 with the intent to occlude the ASD. In 52 of
these patients (10.9%) a BD was not implanted because (a)
there was partial anomalous pulmonary venous connection
(n 5 3), (b) the stretched diameter was too large (.30 mm)
to safely implant the device (n 5 39) or (c) the occluder
came through the ASD (n 5 5) or was unstable (n 5 5)
(Fig. 4). In the latter 10 patients, the occluder was retrieved
through the sheath and the procedure terminated. The data
on the remaining 423 patients who had both the occluder
and counter-occluder implanted across the ASD will be
presented in this article.
Study subjects. The ages of these patients varied between
1.5 and 80 years, with a median of 16 years. One hundred
and eighty-three study subjects (43%) were children below
the age of 10 years and 157 (37%) were adult study subjects
above 18 years of age. Forty-two (10%) were over 50 years
of age. The patients weighed between 7 and 125 kg (median
35 kg). The number of patients undergoing transcatheter
fourth generation BD occlusion at each institution varied
between 3 and 54, with a median of 8.
ASDs and devices. The Qp:Qs was 1.5 to 3.7 with a
median of 2. The stretched diameter of the ASD by balloon
sizing varied between 5 and 30 mm (median 17 mm). The
size of the device selected is generally twice as large as
stretched ASD diameter (10); the ratio of the size of the
device/stretched ASD diameter was 2.35 6 0.8. The num-
ber of different sized devices used were as follows: 25 mm:
23; 30 mm: 62; 35 mm: 71; 40 mm: 109: 45 mm: 73;
50 mm: 57; 55 mm: 12; 60 mm: 16. The most commonly
implanted devices were 35 mm, 40 mm and 45 mm.
Immediate results. Successful device implantation was ac-
complished in 422 (99.8%) out of 423 patients in whom the
device was released or in 422 (89.2%) of 475 patients
brought to the catheterization laboratory with the intent to
occlude the defect. Unbuttoning occurred in 4 (0.9%) of the
remaining 422 patients. These unsuccessful implantations
will be detailed in the “Complications” section.
Qp:Qs was not routinely measured following device
implantation to prevent inadvertent dislodgment of the
device. ECHO-Doppler studies were performed within
24 h after device implantation to evaluate for residual shunt.
Effective occlusion, defined as no (n 5 343) or trivial (n 5
34) residual shunt, was observed in 377 (90%) of 417
patients. Multivariate logistic regression analysis did not
Figure 4. Flow chart of patients taken to cardiac catheterization laboratory with intent to occlude ASD.
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identify any factors predictive of residual shunt. The age
(22.8 6 19.5 vs. 20.6 6 19.4 years; p . 0.1), weight (41.0 6
23.5 vs. 39.5 6 22.7 kg; p . 0.1), Qp:Qs (2.1 6 0.6 vs.
2.1 6 1.4; p . 0.1), stretched ASD diameter (18.8 6 5.3 vs.
17.1 6 5.4 mm; p . 0.05) and device/ASD diameter ratio
(2.34 6 0.45 vs. 2.34 6 0.8; p . 0.1) of the 40 patients with
significant residual shunt are similar to those without
residual shunt.
Complications. Six (1.4%) major complications occurred.
Unbuttoning was the most common complication during
the procedure, and occurred in 4 (0.9%) of the 423 implan-
tations. Unbuttoning rate was similar (p . 0.1) between
cardiologists with (2 in 214; 0.94%) and without (2 in 209;
0.96%) experience in implanting BDs; lack of experience is
defined as performing ,10 cases (4).
In two patients, the unbuttoning occurred in the cathe-
terization laboratory; the device was retrieved via the sheath
and the patients sent to elective surgery later. In the other
two patients, unbuttoning was discovered within 24 h after
the procedure; one patient underwent transcatheter retrieval
of the device components and elective surgery at a later date,
whereas the other patient underwent successful surgical
retrieval along with closure of the ASD on the day following
the procedure. In the fifth patient, whole device emboliza-
tion was discovered 5 h after device placement. The device
was transcatheter retrieved and elective surgical closure of
the ASD was successfully undertaken at a later date. All
three patients with device dislodgment were asymptomatic
and dislodgment was discovered during routine monitoring.
In the final patient, the device was inadvertently implanted
straddling the atrial septum, and a pericardial effusion was
seen on ECHO the following day. Therefore, surgical
intervention was undertaken during which the device was
removed and ASD closed. During surgery, a pinpoint
perforation of the right atrium was noted, presumably
related to device placement, and was repaired. The patient
made excellent recovery and was discharged home two days
later. All six patients had clinical and ECHO follow-up for
slightly more than 12 months and remain asymptomatic.
Follow-up. Follow-up data are available up to five years in
333 (80%) of 417 eligible patients with a median of 24
months (23 6 15 months), for a total of 638 patient-years
of follow-up. The number of patients followed, relative to
the number of patients eligible for follow-up at each
follow-up interval, are as follows: one month: 333/417 5
80%; six months: 310/417 5 74%; one year: 280/380 5
74%; two years: 177/236 5 75%; three years: 88/117 5
75%; four years: 48/63 5 76% and five years: 8/9 5 89%.
During the follow-up reinterventions were required in 21
(5%) patients: one for repair of a mitral valve and 20 for
treatment of residual shunt. The mitral valve perforation,
presumably caused during the direct device placement, was
repaired four weeks after the procedure. At the same time,
the device was removed and the ASD repaired. The residual
shunts were treated either by surgical closure (n 5 11) or
with a second device (n 5 9) 3 to 30 months (median 13)
following initial placement of the fourth generation BD.
The second device was either a BD (n 5 7) or an Amplatz
septal occluder (n 5 2) (11). Actuarial reintervention-free
rates at one, two and five years were 94%, 91% and 89%,
respectively (Fig. 5). Further follow-up after reintervention
was available for six to 12 months; all patients were
asymptomatic and did not require additional intervention.
In the remaining patients, careful scrutiny of the chest
roentgenogram did not reveal any evidence for wire frac-
tures, although this may not be the best method to detect
wire fractures. ECHO studies revealed the device in stable
position and appearing to be incorporated into the atrial
septum. There was no evidence for vegetation or thrombus
formation. There was gradual reduction of the residual
shunts (Fig. 6). There were no deaths during the entire
period of observation.
Figure 5. Graph showing actuarial event-free rates after tranvenous fourth
generation buttoned device occlusion of atrial septal defects. The 95th
confidence intervals were cath: 0.6%; one day: 1.2%; one month: 1.6%; six
months: 2.0%; one year: 2.7%; two years: 3.9%; three years: 5.9%; four
years: 8.2% and five years: 20%.
Figure 6. Time course of residual atrial shunts following buttoned device
(fourth generation) occlusion of atrial septal defects. Percent of patients
with residual shunts (NRS/NE) 5 100, where NRS is the number of
subjects with residual shunt and NE is the number of subjects examined at
a particular follow-up interval. The NRS/NE at varying intervals are as
follows: one day: 115/417; one month: 113/333; six months: 100/310; one
year: 82/280; two years: 43/177; three years: 11/88; four years: 5/48 and five
years: 0/8. Note gradual decrease in percent of patients with residual shunt.
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Comparison with first, second and third generation
devices. The immediate (4) and follow-up (12,13) results
of our international experience with first, second and third
generation BDs are compared with the current experience
with the fourth generation device, reported herein, in Tables
1 and 2. Although the current study cohort is slightly older
and heavier than the first cohort and the stretched ASD
diameter larger, the device/ASD diameter ratio was similar
(Table 1). The percentage of patients in whom the device
was implanted was similar (p . 0.1), as was the effective
occlusion rate (Table 2). The major difference was a
decrease (p , 0.001) in the rate of major complications
(7.8% vs. 1.4%), which is largely related to a decrease (p ,
0.001) in the unbuttoning rate (7.2% vs. 0.9%) (Fig. 7).
Whole-device embolization occurred once in each cohort (1
in 180 vs. 1 in 423; p . 0.1) and is probably related to
inaccurate sizing of the ASD. The duration of follow-up
was slightly longer for the first, second and third generation
cohort than for the fourth generation cohort, which may in
part explain the slightly higher rate (8% vs. 5%) of reinter-
vention with earlier devices.
However, when actuarial reintervention-free rates follow-
ing successful device implantation are compared (Fig. 8),
there was no difference (p . 0.1) between the two cohorts.
Core wire migration, seen in two patients in the first cohort,
was not seen in the fourth generation cohort.
DISCUSSION
The results of this international study demonstrate that
implantation to occlude secundum ASDs with the fourth
generation device is feasible, with minimal probability
(’1%) for device dislodgment. The effective occlusion
(trivial or no residual shunt) rate is high (90%) and the need
for reintervention during follow-up up to five years is low.
The residual shunts decrease and/or disappear with time.
Thus, overall success rate is high at 94%, with actuarial
reintervention-free rates of 89% at three, four and five years.
Patients with unsuccessful implantation and those requiring
treatment during follow-up underwent successful surgical
repair or a second device was implanted.
Table 1. Comparison of Patient, Defect and Device Characteristics
1st, 2nd & 3rd
Generation
Buttoned Device
4th Generation
Buttoned Device p Value
Total number of patients
(intent to close)
200 475 —
Number (%) of patients in
whom the device was
implanted
180 (90%) 423 (89%) . 0.1
Age (yrs) 14.6 6 16.8 20.8 6 19.4 , 0.001
(range 0.6 to 76; median 7) (range 1.5 to 80; median 16)
Weight (kg) 31.6 6 21.4 39.6 6 22.7 , 0.001
(range 3.6 to 105; median 22) (range 7 to 125; median 35)
Size of ASD
Qp:Qs 2.1 6 0.6 2.1 6 1.4 . 0.1
(range 1.5 to 3.8) (range 1.5 to 3.7)
Stretched diameter (mm) 15.8 6 3.8 17.3 6 5.3 , 0.001
(range 5 to 24) (range 5 to 30)
Devices used 25 to 50 mm 25 to 60 mm —
Device/defect ratio 2.3 6 0.3 2.35 6 0.8 . 0.1
Table 2. Comparison of Immediate and Follow-up Results
1st, 2nd & 3rd
Generation
Buttoned Device
4th Generation
Buttoned Device
p
Value
Ratio of device implants to number
of subjects taken to cath lab
180/200 (90%) 423/475 (89%) . 0.1
Ratio of successful implants/number
implanted
166/180 (92.2%) 417/423 (98.6%) , 0.001
Total major complications 14/180 (7.8%) 6/423 (1.4%) , 0.001
Unbuttoning rates 13/180 (7.2%) 4/423 (0.9%) , 0.001
Effective occlusion rates 154/168 (92%) 377/417 (90%) . 0.1
Duration of follow-up, months 46 6 20 (1 month to 7 yrs) 23 6 15 (1 month to 5 yrs) , 0.001
Reintervention rates 14/166 (8%) 21/417 (5%) , 0.02
Actuarial reintervention-free rates
at 1, 2 and 5 years, respectively
after successful implantation*
93.5%, 92.1% and 89.8% 95.3%, 92.6% and 90.5% . 0.1
*See Figure 8.
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The objective of modifying the device by introducing two
radiopaque buttons was to decrease or eliminate the prob-
lem of unbuttoning, which was significant with the first,
second and third generation BDs (4). The unbuttoning rate
was indeed decreased from 7.2% to ,1%; thus the objective
of modifying the device was achieved. Even though there is
no theoretical basis for this particular device modification to
alter effectiveness of occlusion of ASD, either immediate or
during follow-up, we did examine this issue, and the data
(Figs. 7 and 8; Table 2) do indicate that effectiveness is
similar to that of earlier generation devices. Core wire
migration, which occurred in a single batch of defectively
manufactured devices in the first cohort, has since been
corrected without recurrence of the problem with the fourth
generation devices.
Over-the-wire versus direct device placement. The cur-
rent study was not designed to examine the relative merits of
direct versus over-the-wire implantation of the device to
occlude the secundum ASD. This issue was examined in
separate cohorts of the international BD trial (14). On the
basis of these data, it was concluded that the over-the-wire
technique provides better device stability, is less operator-
dependent and avoids injury to the atrial walls and mitral
valve. Because the occluder can be repositioned into the left
atrium if it slips through the defect, retrieval of the occluder
is not necessary, so device economy is also achieved.
Comparison with other devices. The pioneering works of
King and Mills (15,16) and Rashkind (17,18) have led the
way to development of a variety of devices (9,11,19–24).
Most of these were tested in animal models, followed by
clinical trials in human subjects. But, to the best of our
knowledge, none of the devices are, as yet, approved by the
FDA for general clinical use. The selection of one device
over the others becomes difficult in the absence of prospec-
tive, randomized clinical trials. A few studies (25–27) have
examined the results of two to six devices used in sequence
as newer devices became available, but they are neither
prospective nor randomized in their design. Under existing
ethical, economic, technical and medical considerations, it is
unlikely that a prospective randomized clinical trial involv-
ing all the eligible devices is possible. The choice of device
may, therefore, have to be made on the basis of human trials
of each of the individual devices, conducted separately,
sponsored by the device designers or their manufacturers.
Considerations such as size of the device delivery sheath,
availability, cost and ease of mastering device implantation
technique may have to be taken into account, in addition to
safety and effectiveness shown in the clinical trials.
IMMEDIATE RESULTS. Atrial septal defect closure devices,
along with size of device delivery catheter and clinical trial
status, are listed in Table 3. Preliminary experience with
each of these devices (Table 4) (4,18,19,23,28–37) reveals
that the data are similar in regard to rates of device
implantation and dislodgment as well as effectiveness of
occlusion.
MIDTERM RESULTS. Midterm follow-up (defined as six
months to two years) results are available for the clamshell
(38–40), buttoned (3,4,41–43) and atrial septal defect
occluding system (ASDOS) (32) devices. Complete occlu-
sion was demonstrated in 47% (38) to 85% (38–40) of
patients following clamshell device implantation, whereas
complete occlusion rates varied between 79% and 81% after
BD occlusion (3,4,41–43) and 83% with ASDOS (32).
Gradual decrease and disappearance of residual shunt has
been observed with all three devices.
Figure 7. Bar graphs comparing the total complication and unbuttoning
and effective occlusion rates with each cohort. Note significant decrease
(p , 0.00) in major complication rate with the fourth generation device,
which appears to be largely related to a decrease (p , 0.001) in
unbuttoning rate. Effective occlusion, defined as no or trivial residual shunt
(4), has remained similar (p . 0.1).
Figure 8. Graph comparing event-free rates after successful device implan-
tation. This was done so as to assess difference, if any, following first,
second and third generation versus fourth generation buttoned device
occlusion of secundum atrial septal defects. The fourth generation (Gen)
data are depicted by filled squares and the first, second and third generation
by unfilled squares. The number of subjects available for follow-up at each
specified follow-up interval are shown at the bottom of the graph,
appropriately keyed. Note that there is no difference (p . 0.1) by log-rank
test between the two cohorts.
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LONG-TERM RESULTS. Justo (44) and Prieto (45) and their
associates reported long-term follow-up data on a limited
number of patients following clamshell device placement. A
31-month mean follow-up of 45 patients by Justo et al. (44)
revealed actuarial complete ASD closure in 64% 6 15%;
estimated prevalence of arm fractures was 71% 6 21% at
four years. Prieto et al. (45) followed 31 patients for a mean
interval of 41 months. Complete closure was observed in
55% of patients and arm fractures were detected in 84% of
patients. During long-term follow-up (46 6 20 months) of
the 180 BD closures (12,13), 14 (8%) required reinterven-
tion. Actuarial event-free rates at five and seven years were
85% and 85% respectively. Arm fractures were not detected.
There was gradual decrease and disappearance of residual
shunt. In the current study of the fourth generation device
with a median follow-up of 24 months (one month to five
years), reinterventions were required in 5% of patients, with
89% actuarial freedom from reinterventions at three to five
Table 3. Atrial Septal Defect Closure Devices
Device
Size of the
Delivery Sheath Clinical Trial Status
King and Mills device 23F Inactive
Rashkind’s single disc prosthesis 16F Inactive
Rashkind’s double disc device 11F Inactive
Clamshell device 11F Inactive
Buttoned device (1st, 2nd and 3rd generation) 8–11F See 4th generation device
Das Angel Wing device 11F Clinical trials suspended pending
redesigning of the device
Sideris’ centering buttoned device 11F Clinical trials outside the USA
ASDOS 11F Clinical trials outside the USA
Amplatzer 7F/8F Phase II trials
CardioSeal 11F Phase I trials
Fourth generation buttoned device 8F/9F Phase II trials
GORE device 9F Clinical trials outside the USA
Centering-on-demand buttoned device 9F Clinical trials in the USA
ASDOS 5 atrial septal defect occluding system; F 5 French size; USA 5 United States of America.
Table 4. Preliminary Results of ASD Closure Devices (4,18,19,23,28–37)
Device/Author
No. of Subjects
Taken to Cath
Lab with Intent
to Close
No. of Subjects
(%) in Whom
the Device was
Implanted
No. of Subjects
(%) in Whom
Device Dislodgment/
Embolization/
Misplacement
Occurred
No. of Subjects
(%) With Effective
Occlusion*
Hooked device
Rashkind 28 20 (71%) 4 (20%) 13 (65%)
Clamshell
Rome et al. 40 34 (85%) 2 (6%) 12 (63%)**
Buttoned
Rao et al. 200 180 (90%) 12 (7%) 154 (92%)
Das Angel Wing
Weil et al 89 56 (63%) 3 (6%) 37 (66%)
Mendelsohn et al. 75 65 (87%) 7 (11%) †
ASDOS
Sievert et al. 13 12 (92%) 2 (17%) 9 (75%)
Hausdorf et al. 10 9 (90%) 1 (11%) 8 (89%)
Sievert et al. † 200 26 (13%) 79/126 (63%)
Amplatzer
Massura et al. 30 30 (100%) 0 (0%) 27 (90%)
Thanopoulos et al. 18 16 (89%) 1 (6%) 13 (81%)
Wilkins and Goh 33 26 (87%) 2 (8%) 22 (94%)
Hijazi et al. 19 18 (95%) 1 (5%) 16 (89%)
CardioSeal
Moore et al. 157 132 (84%) 2 (1.5%) 82 (63%)
Latson 72 56 (78%) 5 (9%) †
Buttoned-4th generation
This report 475 423 (89%) 6 (1.4%) 377 (90%)
*Effective occlusion defined as no or trivial residual shunt.
**19 of 32 had adequate imaging studies; 12 (63%) of these had no residual shunt.
†No data.
ASD 5 atrial septal defect; ASDOS 5 atrial septal defect occluding system; Cath Lab 5 Cardiac Catheterization
Laboratory; No. 5 number.
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years. No wire migrations or fractures were observed. When
intermediate and long-term follow-up data become avail-
able from the other devices, they should be compared with
the existing data on clamshell, ASDOS and BDs.
In summary, a large number of ASD occluding devices
have been studied in animal models and human subjects.
Some devices have been discontinued (Table 3), some are
currently in clinical trials, but none have been approved by
the FDA for general use. The foregoing data on the fourth
generation device are encouraging, and the device appears to
be clinically useful.
Study limitations. This is a retrospective analysis of data
collected from 40 institutions and has the limitations
associated with any retrospective and multi-institutional
study. Lack of follow-up data in nearly 20% of patients is
another limitation. However, the age (21.9 6 19.1 years),
weight (38.1 6 21.8 kg), Qp:Qs (2.02 1 0.61), stretched
ASD diameter (17.4 6 5.4 mm) and device/defect diameter
ratio (2.4 6 0.4) are similar (p . 0.1) to the entire cohort,
as is the effective occlusion rate (91% [77 of 84]). Therefore,
the follow-up results are unlikely to be different for this
group of patients without follow-up data, compared with
the larger cohort.
Conclusions. In this study, the hypothesis that modifica-
tion of the BD by introducing two buttons into the design
of the occluder will reduce unbuttoning was tested and
confirmed. Both immediate and follow-up effectiveness of
the occlusion remained unchanged compared with earlier
generation BDs. The introduction of the over-the-wire
technique reduced or eliminated injury to the atrial wall and
mitral valve. This evolved device was found to be successful
in 94% of patients, with reintervention-free rates of 89%
during follow-up up to five years. Because of its safety and
effectiveness, the device may become useful for general
clinical applications, although longer than currently avail-
able follow-up duration is needed to confirm these obser-
vations.
Addendum. Since the initial submission of this manu-
script, a number of studies utilizing this and other devices,
not included in the device comparison section, have been
identified, published or presented. These were reviewed and
the updated data can be found in Rao PS. Current Intervent
Cardiol Reports 2000;2:3.
APPENDIX
In addition to the authors, the Buttoned Device Trial
Group includes the following investigators: E. Onorato
(Ospedale Clinicizzato San Donato, San Donato Milanese,
Italy), J.K. Lee (Younsei University, Seoul, Korea), A.M.
Worms and F. Marcon (Centre Hospitalier et Universitaire,
Nancy, France), R. Schrader (University Hospital, Frank-
furt, Germany), J. Losay (Center Chirugical Marie Lan-
nelongue, Paris, France), H. Kulkarni (King Edward Me-
morial Hospital, Mumbai, India), C.W. Chiang (Chang
Gung Memorial Hospital, Taipei, Taiwan), H. Yigao
(Guangdong Cardiovascular Institute, Guangzhou, China),
H.Y. Lee and J.H. Yoon (Wonju Christian Hospital,
Wonju, Korea), R. Bach (Saint Louis University Hospital,
Saint Louis, Missouri), S.H. Kim (Sejong General Hospi-
tal, Puchon, Korea), L. Ballarini (Ospedale Pediatrico
Bembino Gesu, Rome, Italy), P. Lange (German Heart
Institute, Berlin, Germany), M. Leung (Grantham Hospi-
tal, Hong Kong), F. Godart (Centre Hospitalier Regional
Universitaire de Lille, Lille, France), I.F. Palacios (Massa-
chusetts General Hospital, Boston, MA), T. Chatterjee
(University Hospital, Bern, Switzerland), J.M. Neutze and
N. Wilson (Green Lane Hospital, Auckland, New Zea-
land), B. Hwang (Veterans General Hospital-Aipei, Taipei,
Taiwan), J.K. Wang (National Taiwan University Hospital,
Taipei, Taiwan), R. Sengun (117th Hospital, Hangzhou,
China), H. Luo (Gungdong Province Peoples Hospital,
Guangzhou, China), A. Kaneva (National Center for Car-
diovascular Diseases, Sofia, Bulgaria), E. Pesonen (Helsinki
University Central Hospital, Helsinki, Finland), L. Solymar
(SU/East Hospital, Gothenburg, Sweden), and A.B. Mehta
(Jaston Hospital, Mumbai, India).
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